Lifeboat Foundation

Rudrapur, Uttrakhand, India — July 02, 2017

Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational regenerative therapeutic applications, has announced that it is continuing to advance their novel, multi-modality clinical intervention in the state of brain death in humans.

“We have proactively continued to advance our multi-modality protocol, as an extended treatment before extubation, in an attempt to reverse the state of brain death” said Mr.Pranjal Agrawal, CEO Revita Life Sciences. “This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye opening and finger movements, with corresponding transient to permanent reversal changes in EEG patterns.”

Continue reading “Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects” »

The June Journal Club video is now available for your viewing pleasure. Dr. Oliver Medvedik talks about telomeres and cellular reprogramming in this latest edition of our new live streamed monthly show.

It has been a busy few months since we launched our Lifespan Heroes campaign on Lifespan.io the aim of which is to help us expand the scale and scope of our activities.

Continue reading “Journal Club June 2017 Video Available” »

Gearing up for clinical trials.

Liz discusses how we can overcome the limits on human health and lifespan; elaborating on BioViva’s role as a translational engine to provide access to cutting-edge therapies for those most in need.

http://journey100.org | Journey to 100 is a world-exclusive conference exploring ideas for a new and sustainable approach to lifelong health. The day kick starts a 10-year project that aims to make Guernsey the first community in the world to break through the 100-year life expectancy barrier.

Continue reading “BioViva at Journey to 100” »

As if anyone needed any excuse to drink more beer, a team of researchers have managed to produce an alcoholic beverage that also contains probiotics. In a novel breakthrough, they claim that the beer could help improve gut health and immunity, though the science is still out on that last one.

There are plenty of dairy-based probiotics, but currently there are no beers that also contain probiotics, mainly because beer contains something known as hop acids, which limit the growth and survival of potential probiotics. This spurred the researchers at the National University of Singapore to see if they could manage it.

They succeeded in developing a sour beer that can support the probiotic strain known as Lactobacillus paracasei L26. This particular probiotic is already found in the human gut, and there is some evidence that it might be able to regulate the immune system.

Continue reading “Researchers Produce World’s First Probiotic Beer” »

CRISPR technology is transforming biomedical research and is at the heart of numerous recent discoveries — but if no one can pay for treatments it produces, how will we make use of it? Experts have a range of ideas to solve this knotty problem.

Rapid developments in brain-machine interfacing and neuroprosthetics are revolutionizing the way we treat paralyzed people, but the same technologies could eventually be put to more generalized use—a development that’ll turn many of us into veritable cyborgs. Before we get to that point, however, we’ll need to make sure these neural devices are safe, secure, and as hacker-proof as possible.

In anticipation of our cyborg future, researchers from the Wyss Center for Bio and Neuroengineering in Geneva Switzerland have published a new Policy Forum paper in Science titled, “Help, hope, and hype: Ethical dimensions of neuroprosthetics.” The intent of the authors is to raise awareness of this new breed of neurotechnologies, and the various ways they can be abused. Importantly, the researchers come up with some ways to mitigate potential problems before they arise.

Keith Comito introduces the Lifespan Heroes campaign and how we as a community can support the development of new therapies to treat age-related diseases for a healthier and longer life.

Link to the Lifespan Heroes campaign: https://www.lifespan.io/campaigns/join-us-become-a-lifespan-hero/

Link to all our campagins: https://www.lifespan.io

Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.

“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

Continue reading “Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement” »

The aorta is an important blood vessel, to say the least. It’s the body’s main artery, carrying blood from the heart up to the head and down to the other major organs. That’s why aortic aneurysms, or weak spots in the aorta, are so concerning: if they break, the extreme blood loss is often fatal.

Seattle-area biotech startup Aortica is working on a personalized approach to treating aortic aneurysms, specifically complex abdominal aortic aneurysms, which are more tricky to treat. The company has closed just over $1 million out of a $4 million round of insider funding to further develop the treatment, and Aortica CEO and founder Thomas Douthitt told GeekWire the company has commitments to finish the full $4 million round.

Continue reading “Biotech startup Aortica raising $4M to develop personalized blood vessel stents for aortic aneurysms” »